Clinical effect of irbesartan combined with metoprolol tartrate tablets on heart failure with preserved ejection fraction

Abstract

Objective To investigate the clinical effect of irbesartan combined with metoprolol tartrate tablets on heart failure with preserved ejection fraction(HFPEF). Methods Eighty-seven cases of HFPEF were divided into two groups by the difference of treatment measures, 43 cases treated with metoprolol tartrate tablets as control group, and 44 cases treated with combined therapy of irbesartan as observation group, the maximum drop rate of left indoor pressure(-dp/dtmax), N-terminal pro-B-type natriuretic peptide(NT-proBNP) and 6-minute walk test(6MWT) of the two groups was analyzed. Results After treatment, they-dp/dtmax of observation group was (1 347.27±180.26) mmHg/s (1 mmHg=0.133 kPa), which was higher than that of control group[(1 290.27±200.35)mmHg/s], and the NT-proBNP level was (753.26±227.38) pg/ml, which was lower than that of the control group[(873.33±226.26) pg/ml], there were significant differences(P<0.05). The ultrasonic index and 6MWT were all better in the observation group than those in the control group, the differences were significant (P<0.05). Conclusions Irbesartan combined with metoprolol tartrate tablets have significant effect on HFPEF patients, which can effectively improve the-dp/dtmax, NT-proBNP, as well as improve the ultrasonic index and 6 MWT, which can be promoted. Key words: Heart failure with preserved ejection fraction; Irbesartan; Metoprolol tartrate tablets; N-terminal pro-B-type natriutretic peptide; Ultrasonic index